依达拉奉联合降纤酶治疗进展性脑梗死的疗效观察

Curative effects of Edaravone combined Batroxobin on treating progressive cerebral infarction

目的观察依达拉奉联合降纤酶治疗进展性脑梗死(PCI)的疗效。方法对50例PCI患者用依达拉奉30mg加入生理盐水100ml静脉滴注,每天2次,连用14d;降纤酶首次10BU,以后5BU加入生理盐水250ml静脉滴注,隔日1次,共4次。在治疗前、后进行欧洲卒中量表(ESS)和Barthel指数(BI)评分、血浆纤维蛋白原(Fib)含量检测;并与单用降纤酶的对照组比较。结果联合治疗组治疗7d、14d、21d时的ESS评分显著高于对照组(均P<0.05);治疗后血浆Fib水平明显低于治疗前(P<0.01),与对照组差异无统计学意义。联合治疗组的显效率(72%)和有效率(90%)明显高于对照组(42%、66%)(均P<0.05)。两组各有3例尿常规出现少量红细胞,联合治疗组有4例丙氨酸转氨酶(ALT)轻度升高。结论依达拉奉联合降纤酶治疗PCI有显著疗效,无明显不良反应。

Objective To observe the curative effects of Edaravone combined Batroxobin on treating progressive cerebral infarction （PCI）. Methods 50 patients with PCI were treated with Edaravone 30 mg intravenous drip twice a day for 14 d. Meanwhile, Batroxobin 10 BU on the first day, subsequently 5 BU intravenous drip, once for next day, total 4 times. European stroke scale （ESS） , Barthel index and plasma fibrinogen （Fib） level were tested before and after treatment. Compared with the patients （control group） treated with Batroxobin only. Results The score of ESS in united treatment group on 7th, 14th, 21th day were obviously higher than those in the control group （ all P 〈 0.05 ）. The levels of plasma Fib in two groups were significantly decreased than befor treatment and no significant differences after treatment. The excellent rate （ 72% ） and the effective rate （ 90% ） of the united treatment group were obviously higher than those of the control group （42% and 66%, respectively） （all P 〈0. 05）. There were 3 patients with few erythroeytes in urine in each group. There were 4 patients in the united treatment group with slight elevation of alanine aminotransferase. Conclusion Edaravone combined Batroxobin are remarkable effective on PCI andwithout obvious advers reaction.